Relugolix Combination Therapy Efficacy Data Reported
A clinical study shows that the daily treatment maintains contraceptive efficacy while monitoring bone health in women.
Updated on Oct. 30, 2026 in Women’s Health
Live Poll
Would you rely on a medication for contraception if it was not primarily approved for that purpose?
The SERENE clinical trial, which presented its findings in October 2026, evaluated the efficacy of daily relugolix combination therapy in 981 women. The study recorded a 1.2% cumulative pregnancy rate over the course of one year.
Why it matters
The trial provides essential data on the contraceptive reliability of relugolix for women managing conditions like uterine fibroids. Understanding these outcomes helps clinicians balance symptom relief with potential side effects such as bone mineral density changes.
The study found a 1.2% cumulative pregnancy rate among 981 participants, with an at-risk Pearl Index of 1.27. Researchers observed that while most maintained bone density, 193 participants withdrew due to bone loss exceeding 3%.
The players
American Society for Reproductive Medicine
This is a professional association dedicated to the advancement of reproductive science and medicine.
The details
Participants used the medication to suppress luteinizing and follicle-stimulating hormones, which in turn reduces ovarian estradiol and progesterone. While 86.7% of the cohort suffered from uterine fibroids, the trial also monitored patients for potential bone mineral density decreases in the lumbar spine, total hip, and femoral neck.
Timeline
October 2026 findings were discussed at the American Society for Reproductive Medicine meeting.
The Big Picture
The SERENE clinical trial establishes a new benchmark for evaluating the secondary effects of hormone-suppressing treatments. This research helps bridge the gap between symptom-specific therapy and broader reproductive health monitoring.
Women considering this treatment should discuss bone density monitoring with their healthcare provider to mitigate potential risks. The data confirms the medication's effectiveness as a contraceptive, which is a critical consideration for those managing fibroids or endometriosis.
The takeaway
Patients using relugolix combination therapy should prioritize regular screenings to ensure their bone mineral density remains within healthy limits. This trial highlights the importance of individualized treatment plans when managing reproductive conditions that require hormonal suppression.
Further reading
Learn more about the latest developments in Women’s Health.
Source note: This article includes information reported by Medscape.
Live Poll
Would you rely on a medication for contraception if it was not primarily approved for that purpose?
